2020
Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor K. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Frontiers In Immunology 2020, 11: 776. PMID: 32547535, PMCID: PMC7274207, DOI: 10.3389/fimmu.2020.00776.Peer-Reviewed Original ResearchConceptsLipoprotein receptor-related protein 4Chronic inflammatory demyelinating polyneuropathyMuSK myasthenia gravisMyasthenia gravisDisease subtypesPathogenic autoantibodiesNeuromyelitis opticaPemphigus vulgarisFab-arm exchangeNeuromuscular junctionAChR myasthenia gravisDistinct immune mechanismsInflammatory demyelinating polyneuropathyAutoimmune myasthenia gravisContribution of complementMuscle-specific kinaseNicotinic acetylcholine receptorsSubtype of diseaseDemyelinating polyneuropathyMG subtypesMG patientsAutoantibody productionClinical benefitAutoimmune diseasesAutoimmune pathology
2016
Restoring immune tolerance in neuromyelitis optica
Steinman L, Bar-Or A, Behne J, Benitez-Ribas D, Chin P, Clare-Salzler M, Healey D, Kim J, Kranz D, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei C, Weiner H, Zamvil S, Yeaman M, Smith T, Consortium G, Aktas O, Amezcua L, Appiwatanakul M, Asgari N, Banwell B, Bennett J, Bowen J, Cabre P, Chitnis T, Cohen J, De Seze J, Fujihara K, Han M, Hellwig K, Hintzen R, Hooper D, Iorio R, Jacob A, Jarius S, Kim H, Kissani N, Klawiter E, Kleiter I, Lana-Peixoto M, Leite M, Levy M, Lublin F, Draayer Y, Marignier R, Matiello M, Nakashima I, O’Connor K, Palace J, Pandit L, Paul F, Prayoonwiwat N, Riley C, Ruprecht K, Saiz A, Siritho S, Tenembaum S, Weinshenker B, Wingerchuk D, Würfel J. Restoring immune tolerance in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation 2016, 3: &na;. PMID: 27648463, PMCID: PMC5015539, DOI: 10.1212/nxi.0000000000000276.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNMO/SDNeuromyelitis opticaImmune toleranceAquaporin-4 (AQP4) water channel proteinKey immune mechanismsImmune tolerizationDevelopment of cancerEmpirical therapyOptic nerveRandomized trialsImmunologic suppressionAutoimmune diseasesSerious infectionsAstrocyte dysfunctionCurrent therapiesImmune mechanismsSpinal cordClinical variantsDominant autoantigenAquaporin-4Therapeutic restorationRestorative techniquesTherapyOpticaPatientsRestoring immune tolerance in neuromyelitis optica
Bar-Or A, Steinman L, Behne J, Benitez-Ribas D, Chin P, Clare-Salzler M, Healey D, Kim J, Kranz D, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei C, Weiner H, Zamvil S, Smith T, Yeaman M, Aktas O, Amezcua L, Appiwatanakul M, Asgari N, Banwell B, Bennett J, Bowen J, Cabre P, Chitnis T, Cohen J, De Seze J, Fujihara K, Han M, Hellwig K, Hintzen R, Hooper D, Iorio R, Jacob A, Jarius S, Kim H, Kissani N, Klawiter E, Kleiter I, Lana-Peixoto M, Leite M, Levy M, Lublin F, Draayer Y, Marignier R, Matiello M, Nakashima I, O’Connor K, Palace J, Pandit L, Paul F, Prayoonwiwat N, Riley C, Ruprecht K, Saiz A, Siritho S, Tenembaum S, Weinshenker B, Wingerchuk D, Würfel J. Restoring immune tolerance in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation 2016, 3: &na;. PMID: 27648464, PMCID: PMC5015540, DOI: 10.1212/nxi.0000000000000277.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNMO/SDImmune toleranceAquaporin-4Neuromyelitis optica spectrum disorderNormal host defense mechanismsOptica spectrum disorderHost defense mechanismsOral tolerizationNeuromyelitis opticaOptic nerveParticular brain regionsAutoimmune diseasesAstrocyte functionSpinal cordClinical variantsNovel therapiesDominant autoantigenClinical developmentPotential cureB cellsBrain regionsExperimental modelDiseaseCharacteristic phenotypeAutoantigensChapter 27 Current and future immunotherapy targets in autoimmune neurology
Hu MY, Stathopoulos P, O’connor K, Pittock SJ, Nowak RJ. Chapter 27 Current and future immunotherapy targets in autoimmune neurology. Handbook Of Clinical Neurology 2016, 133: 511-536. PMID: 27112694, DOI: 10.1016/b978-0-444-63432-0.00027-x.ChaptersConceptsAutoimmune neurologic disordersNeurologic disordersChronic inflammatory demyelinating polyradiculoneuropathyInflammatory demyelinating polyradiculoneuropathyPrior treatment responseLarge case seriesAbsence of cancerAutoimmune neurologyChronic immunotherapyDemyelinating polyradiculoneuropathyMyasthenia gravisNeuromyelitis opticaCase seriesOncologic therapyTreatment trialsImmunotherapy targetClinical severityTreatment strategiesTreatment responseAntibody typeMonoclonal antibodiesAnecdotal reportsNew drug discoveryDisordersImmunotherapy